RET inhibitor for use in treating cancer having a RET alteration | Patent Number 11872192

US 11872192 B2
Application Number17377885
Publication NumberUS 20220175773 A1
Pendency2 years, 6 months, 4 days
Filled DateJul 16, 2021
Priority DateApr 3, 2018
Publication DateJun 9, 2022
Expiration DateApr 2, 2038
Inventor/ApplicantsErica Evans Raab
Beni B. Wolf
ExaminesWARD, PAUL V
Art Unit1624
Technology Center1600
Assignments
Rigel Pharmaceuticals
Current
Blueprint Medicines Corporation
Original
Law Firm
You must be logged in to view
Login
Attorneys
Subscription-Only
View Concierge Program
Patent Prosecution report image

Empower your practice with Patexia Publication Prosecution IP Module.

Get access to our exclusive rankings and unlock powerful data.
Check our Latest ReportPurchase IP Module

Looking for a Publication Attorney?

Get in touch with our team or create your account to start exploring a network of over 120K attorneys.